TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $883.66m
- $528.80m
- $107.46m
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates
Brief: Theravance Biopharma Q2 Operating Income USD -8.277 Million
Press Digest: Canada - June 30
Deals of the day-Mergers and acquisitions
Zymeworks falls after $929 million Theravance buyout deal
Deals of the day-Mergers and acquisitions
Zymeworks expands beyond cancer with $929 million Theravance acquisition (updated)
Theravance slips after Zymeworks' $929 mln buyout deal
Zymeworks strikes $929 million deal for Theravance Biopharma
Brief: Zymeworks Said To Near $929 Million Deal For Theravance - Bloomberg News
Ireland's Theravance Biopharma Q1 revenue beats estimates on YUPELRI growth
Ireland's Theravance Biopharma Q4 revenue misses expectations
Corrected: BRIEF-Theravance Biopharma Q4 Operating Income USD 20.012 Million
U.S. STOCKS ON THE MOVE-Versant Media Group, Lithium miners, Expedia Group
U.S. STOCKS ON THE MOVE-Expedia Group, Blue Owl Capital, Enphase Energy
Theravance falls as co weighs options including possible sale after drug trial failure
NASDAQ RESUMED AT 09:00 AM
Theravance plans strategic review, including possible sale, after drug trial failure (updated)
Theravance Biopharma's blood pressure drug fails to meet main goal in late-stage trial